Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Inhibition of Nuclear Factor Kappa B (NFkB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) By Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib

Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Sarah Belliotti, B.A., Cory Mavis, MSc, Juan Gu, PhD, Myron S. Czuczman, MD

Blood (2014) 124 (21): 1768.

https://doi.org/10.1182/blood.V124.21.1768.1768

Published: 2014

Journal Articles

Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

Kai Xue, MD, Juan Gu, PhD, Cory Mavis, MSc, Francisco Hernandez, MD, Myron S. Czuczman, MD, Ye Guo, MD

Blood (2014) 124 (21): 5486.

https://doi.org/10.1182/blood.V124.21.5486.5486

Published: 2014

Journal Articles

MLN4924 An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE) Is Active In Pre-Clinical Models Of Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma

Sarah Belliotti, B.A., Juan Gu, PhD, Cory Mavis, BSc, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 4409.

https://doi.org/10.1182/blood.V122.21.4409.4409

Published: 2013

Journal Articles

Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development

Juan Gu, PhD, Vivek Yanamadala, Cory Mavis, BSc, MSc, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2013) 122 (21): 4413.

https://doi.org/10.1182/blood.V122.21.4413.4413

Published: 2013

Journal Articles

Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models

Cory Mavis, BSc, MSc, Juan Gu, PhD, Joseph Skitzki, MD, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2013) 122 (21): 1828.

https://doi.org/10.1182/blood.V122.21.1828.1828

Published: 2013

Journal Articles

Metformin Lowers The Mitochondrial Potential Of Lymphoma Cells and Its Use During Front-Line Rituximab-Based Chemo-Immunotherapy Improves The Clinical Outcome Of Diffuse Large B-Cell Lymphoma

Anil Singh, MD, Juan Gu, PhD, Vivek Yanamadala, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 1825.

https://doi.org/10.1182/blood.V122.21.1825.1825

Published: 2013

Journal Articles

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors

Sarah Frys, BSc, Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Juan Gu, PhD, John Gibbs, MD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2012) 120 (21): 1649.

https://doi.org/10.1182/blood.V120.21.1649.1649

Published: 2012

Journal Articles

Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL)

Juan Gu, PhD, Francisco Hernandez-Ilizaliturri, MD, Gregory P. Kaufman, Cory Mavis, BSc, MSc, Myron S. Czuczman, MD

Blood (2012) 120 (21): 1655.

https://doi.org/10.1182/blood.V120.21.1655.1655

Published: 2012

Journal Articles

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

Juan Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, Karen E Thudium, George Deeb, MD, John Gibbs, MD, Myron S. Czuczman, MD

Blood (2011) 118 (21): 4967.

https://doi.org/10.1182/blood.V118.21.4967.4967

Published: 2011

Journal Articles

The Novel Proteasome Inhibitor Carfilzomib (CFZ) Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents in Rituximab-Chemotherapy Resistant Lymphoma Through Inducing G2/M Cell Cycle Arrest and Cell Death

Juan Gu, PhD, Natalie M Czuczman, Gregory P. Kaufman, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2011) 118 (21): 4970.

https://doi.org/10.1182/blood.V118.21.4970.4970

Published: 2011

Journal Articles

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines,

Cory Mavis, BSc, MSc, Sarah Frys, BSc, Juan Gu, PhD, John Gibbs, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2011) 118 (21): 3734.

https://doi.org/10.1182/blood.V118.21.3734.3734

Published: 2011

Journal Articles

Carfilzomib (CFZ): A Novel Proteasome Inhibitor That Induces Cell Cycle Arrest and Cell Death In Rituximab-Chemotherapy Resistant Lymphoma and Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents

Juan Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Gregory P. Kaufman, Cory Mavis, BSc, MSc, Myron S. Czuczman, MD

Blood (2010) 116 (21): 4908.

https://doi.org/10.1182/blood.V116.21.4908.4908

Published: 2010

Journal Articles

MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines

Juan Gu, PhD, Patil Ritesh, MD, MPH, Cory Mavis, BSc, MSc, George Deeb, MD, John Gibbs, MD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2010) 116 (21): 3939.

https://doi.org/10.1182/blood.V116.21.3939.3939

Published: 2010

NARROW

Inhibition of Nuclear Factor Kappa B (NFkB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) By Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib

Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

MLN4924 An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE) Is Active In Pre-Clinical Models Of Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma

Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development

Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models

Metformin Lowers The Mitochondrial Potential Of Lymphoma Cells and Its Use During Front-Line Rituximab-Based Chemo-Immunotherapy Improves The Clinical Outcome Of Diffuse Large B-Cell Lymphoma

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors

Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL)

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

The Novel Proteasome Inhibitor Carfilzomib (CFZ) Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents in Rituximab-Chemotherapy Resistant Lymphoma Through Inducing G2/M Cell Cycle Arrest and Cell Death

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines,

Carfilzomib (CFZ): A Novel Proteasome Inhibitor That Induces Cell Cycle Arrest and Cell Death In Rituximab-Chemotherapy Resistant Lymphoma and Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents

MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only